Jinwon Life Sciences Begins Phase 2 Clinical Trial of COVID-19 Treatment 'GLS-1027' in Korea
[Asia Economy Reporter Lee Gwanju] Jinwon Life Sciences announced on the 23rd that it will begin domestic clinical research on the oral COVID-19 treatment candidate substance 'GLS-1027.'
The Phase 2 clinical trial of GLS-1027 is being conducted in multiple countries including the United States and Europe. Currently, out of 132 subjects, 116 have been enrolled, and 87 subjects have completed the clinical trial. The company explained that 29 subjects are currently undergoing the clinical trial. The domestic clinical trial will be conducted on 16 subjects.
Hot Picks Today
"You Might Regret Not Buying Now"... Overseas Retail Investors Stirred by News of Record-Breaking Monster Stocks' IPOs
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Mistaken for the Flu, Left Untreated... Death Toll Surges as WHO Declares Emergency (Comprehensive)
- Jinwoo Sunim: "We Must Abandon the Extremes of Surviving by Defeating Others"
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Park Wongeun, CEO of Jinwon Life Sciences, stated, "Since the administration and clinical evaluation period of GLS-1027 is short, within two months, we will promptly complete the enrollment of the remaining 16 subjects at domestic clinical institutions, secure interim clinical results within the first half of this year, and prepare to enter Phase 3 clinical trials."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
